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Abstract
Objective—Rare copy number variants have been implicated in different neurodevelopmental
disorders, with the same copy number variants often increasing risk of more than one of these
phenotypes. In a discovery sample of 22 schizophrenia patients with an early onset of illness (10–
15 years of age), the authors observed in one patient a maternally derived 15q11-q13 duplication
overlapping the Prader-Willi/Angelman syndrome critical region. This prompted investigation of
the role of 15q11-q13 duplications in psychotic illness.
Method—The authors scanned 7,582 patients with schizophrenia or schizoaffective disorder and
41,370 comparison subjects without known psychiatric illness for copy number variants at 15q11-
q13 and determined the parental origin of duplications using methylation-sensitive Southern
hybridization analysis.
Results—Duplications were found in four case patients and five comparison subjects. All four
case patients had maternally derived duplications (0.05%), while only three of the five comparison
duplications were maternally derived (0.007%), resulting in a significant excess of maternally
derived duplications in case patients (odds ratio=7.3). This excess is compatible with earlier
observations that risk for psychosis in people with Prader-Willi syndrome caused by maternal
uniparental disomy is much higher than in those caused by deletion of the paternal chromosome.
Conclusions—These findings suggest that the presence of two maternal copies of a fragment of
chromosome 15q11.2-q13.1 that overlaps with the Prader-Willi/Angelman syndrome critical
region may be a rare risk factor for schizophrenia and other psychoses. Given that maternal
duplications of this region are among the most consistent cytogenetic observations in autism, the
findings provide further support for a shared genetic etiology between autism and psychosis.
Genomic microdeletions and microduplications (commonly termed copy number variants)
are now known to contribute to the etiology of schizophrenia (1–4), autism (5, 6), and
intellectual disability (7, 8). In schizophrenia and related psychoses, the most robust findings
concern microdeletions at chromosomes 1q21.1, 15q11.2, 15q13.3, and 22q11.2 (2–4) as
well as the NRXN1 gene (9) and micro-duplications at chromosomes 16p11.2 (10) and
16p13.1 (11). The finding of a nonspecific relationship between neurodevelopmental
phenotypes and specific copy number variants appears to be a general feature. For example,
the schizophrenia-related deletion at 1q21.1 has been reported in cases of autism (6) and
intellectual disability (7). The same appears to be true for deletions at 15q13.3 (8) and
15q11.2 (12) and duplications at 16p11.2 (6) and 16p13.1 (13). That the same copy number
variants associate with schizophrenia, autism, intellectual disability, and other
neurodevelopmental disorders indicates a genetic overlap among these seemingly disparate
diagnoses.
Aiming to discover novel pathogenic copy number variants, we performed a genome-wide
copy number variant scan of 22 Danish schizophrenia patients with an early onset of disease
(aged 10–15 years), under the premise that developmental forms of the disorder would be
particularly enriched in this group (1). One of the patients carried a 6-Mb duplication of
chromosome 15q11.2-q13.1. This duplication involves the Prader-Willi syndrome (Online
Mendelian Inheritance in Man [OMIM] number: 176270) and Angelman syndrome (OMIM
number: 105830) critical region. These syndromes derive, respectively, from paternal and
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maternal chromosomal deletions (as well as other mechanisms [see Discussion section]).
Duplications of the Prader-Willi/Angelman syndrome critical region were recognized in
several case reports in the mid-1990s as a separate genomic syndrome, the 15q11.2-q13.1
duplication syndrome (OMIM number: 608636), which commonly includes features such as
autism, intellectual disability, seizures, developmental delay, and minor dys-morphic
features (macrocephaly, down-slanting palpebral fissures, expressionless face), most often
when the duplications are maternally derived (14–16). These duplications are currently
among the most consistent cytogenetic findings in autism spectrum disorders, estimated to
account for 0.5%–3% of all cases (17–19), although the more realistic rate is closer to
approximately 0.6%, based on 13 observations in the largest study, which consisted of 2,268
cases (18).
Given the evidence that this region is important in different neurodevelopmental disorders,
we investigated the involvement of chromosome 15q11-q13 duplications in schizophrenia
and related psychoses in a large European sample consisting of 7,582 patients affected with
schizophrenia or schizoaffective disorder and 41,370 comparison subjects. Since we did not
have DNA samples for many of the identified carriers’ parents, we used a methylation-
sensitive Southern hybridization analysis to determine the parental origin of the
duplications. This analysis distinguishes between maternally and paternally derived
duplications without genotyping the parents of carriers.
Method
Samples and Genotyping
Danish sample (discovery and follow-up assessment)—The Danish sample
consisted of 524 patients clinically assigned with a diagnosis of schizophrenia according to
ICD-10, without ever having received a diagnosis of mania or bipolar illness (F30-31).
Information on all hospital contacts as well as corresponding principal ICD-8 (1969–1994)
and ICD-10 (1994–2006) diagnoses was obtained through the Danish Psychiatric Central
Register (20). The diagnoses were verified by an experienced psychiatrist using the OPCRIT
checklist, with 96% of patients who fulfilled ICD-10 criteria for schizophrenia also fulfilling
DSM-IV criteria. The majority (85%) of patients were ethnic Danes, while 15% of patients
had one Caucasian parent born in another North European country. The comparison group
consisted of 477 healthy subjects from the Danish Blood Donor Corps in the Copenhagen
area. Patients with an inpatient admission before age 16 (age: 12–15 years [N=22]) were
assessed in the discovery sample, while the remaining patients, as well as all comparison
subjects, were assessed in the follow-up sample. The 22 patients from the discovery sample
were genotyped on the Illumina HumanCNV370 microarray at deCODE Genetics
(Reykjavik, Iceland), and the follow-up sample was genotyped on the Illumina Human610-
Quad array, described elsewhere (11) (for further details, see Table 1 in the data supplement
accompanying the online version of this article). Copy number variant calling was done
using the PennCNV algorithm (21) and verified through visual inspection of log-R ratios
and B-allele frequencies in the 15q proximal region.
SGENE-plus study follow-up sample—A total of 3,879 persons diagnosed with
schizophrenia or schizoaffective disorder and 35,590 comparison subjects, all from six
European populations, were successfully examined for copy number variants at the locus
studied in the present analyses. An additional 5,773 genotyped samples of individuals of
Icelandic origin were examined but excluded from association analysis because of other
psychiatric or developmental disorders (autism, bipolar disorder, attention deficit
hyperactivity disorder [ADHD], dyslexia, and alcoholism) and/or first-degree relationships
to schizophrenia patients. A full description of the sample and genotyping is provided
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elsewhere (11) (also see Table 1 in the data supplement). Copy number variant calling was
done using the PennCNV algorithm (21) and verified through visual inspection of log-R
ratios and B-allele frequencies in the 15q proximal region.
International schizophrenia Consortium sample—The International Schizophrenia
Consortium sample consisted of 3,391 patients with schizophrenia or schizoaffective
disorder and 3,181 comparison subjects, all of European descent. Full description of the
sample, genotyping, and copy number variant calling is provided elsewhere (3). A total of
661 patients and 670 comparison subjects from Aberdeen, Scotland, overlap between the
SGENE-plus and International Schizophrenia Consortium samples and were only counted
once in the present study (also see Table 1 in the data supplement).
Cardiff University sample—The Cardiff University sample consisted of 471 affected
individuals (schizophrenia patients [N=447]; schizoaffective disorder patients [N=24]) and
2,792 comparison subjects, the latter being from the Wellcome Trust Case Control
Consortium. The comparison subjects were volunteers from the National Blood Service and
were born in the United Kingdom during 1 week in 1958. Details of the sample as well as
genotyping and copy number variant calling are provided elsewhere (4) (also see Table 1 in
the data supplement).
Ethical approval was obtained from the local ethics committees at each study site. After
complete description of the study to the subjects, written informed consent was obtained.
Methylation-Sensitive Southern Analysis
We performed a methylation-sensitive Southern hybridization on 12 identified carriers to
determine the parental origin of 15q11-q13 duplications. This method has previously been
applied for this purpose (22). It exploits the different methylation patterns in paternal and
maternal chromosomes in this region, and thus parental origin can be established without
genotyping parents of carriers. However, this assay cannot distinguish between inherited and
de novo duplications. DNA was digested with the XbaI and methylation-sensitive NotI
enzymes, and the products ran on agarose gel. We constructed a probe containing the exon
alpha of SNPRN, which maps to a region duplicated in all 12 carriers (Human Genome
[National Center for Biotechnology Information Build 36]: chromosome, 15:22,751,022–
22,751,415), and performed a Southern hybridization of the digested DNA using standard
techniques. The probe detects a 4.2-kb band from methylated maternal DNA and a 0.9-kb
band from unmethylated paternal DNA in the XbaI and NotI digestion. Hybridization
intensity was quantified using Kodak 1D Image Analysis Software, v.3.5, (Rochester, N.Y.)
and ratios between intensities of paternal and maternal bands calculated to determine dosage
after subtracting background emission. Full details of the method and analysis are provided
in section 2 of the data supplement.
Results
In addition to one discovery sample patient (case 1), we identified the following 11 15q11-
q13 duplication carriers: one male German schizophrenia patient (case 2), one female
schizoaffective disorder patient (case 3) and one male schizophrenia patient (case 4) from
the United Kingdom, one female Icelandic schizophrenia patient (case 5), one female
Icelandic bipolar I disorder patient (case 6), one female Icelandic autism patient (case 7),
and five female Icelandic comparison subjects (comparison subjects 1–5). Case patients 6
and 7 were identified from the 5,773 individuals in the Icelandic sample who had a
psychiatric or developmental disorder other than schizophrenia or who were first-degree
relatives of a schizophrenia patient. These individuals were excluded from case-control
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association analysis. Case patients 2, 6, and 7 and comparison subjects 2, 4, and 5 carried
duplications corresponding to those found in the Danish discovery sample patient (at
breakpoint [BP] 1–BP3 [Table 1, Figure 1]). Case patients 3 and 4 and comparison subjects
1 and 3 carried a slightly smaller duplication corresponding to the Prader-Willi/Angelman
syndrome critical region (BP2, BP3), while case patient 5 carried a roughly 9-Mb
duplication spanning across BP1–BP4 and a part of the region between BP4 and BP5. The
duplications in case patients 2–4 have been reported in previous genome-wide copy number
variant studies in schizophrenia (3, 4, 23). However, each of these studies only found one
duplication and parental origin was not assessed, and thus the duplications were not
discussed specifically in these studies.
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Parental Origin of Duplications
We performed a methylation-sensitive Southern analysis of all 12 duplication carriers and
found that all seven individuals with a neuropsychiatric diagnosis (cases 1–7) carried
maternally derived duplications. Comparison subjects 3–5 also carried maternally derived
duplications, while comparison subjects 1 and 2 carried paternally derived duplications
(Figure 1, Table 1 [also see section 2 in the data supplement]). A two-sided Fisher’s exact
test based only on the follow-up schizophrenia/ schizoaffective disorder case samples (cases
2–5) showed a nominally significant overrepresentation of maternally derived duplications,
relative to comparison subjects (case patients [N=4/7,582] versus comparison subjects
[N=3/41,370]: p=0.01, odds ratio=7.3, 95% confidence interval=1.2–50).
Phenotypic Features of Duplication Carriers
It is notable that case patient 6 has severe psychotic features, although the patient met study
criteria for bipolar disorder and therefore was not included in the association analysis for
schizophrenia/schizoaffective disorder, while case patient 7 was diagnosed with childhood
autism, mild intellectual disability, and specific developmental disorder of motor function.
Details for all 12 carriers, including primary diagnosis, sex, age at onset, and family history
of psychiatric illness as well as the most commonly reported phenotypic features of 15q11-
q13 duplications, are summarized in Table 1. Detailed summaries for case patients 1–7 are
presented in section 3 of the data supplement.
Some but not all case patients had an early age at onset of psychiatric illness. Case patient 2
was diagnosed with a developmental language disorder and early childhood autism features
prior to a diagnosis of schizophrenia at 18 years of age (see section 3 in the data
supplement). Case patients 4 and 6 had an age at onset of 16 and 13 years, respectively.
Case patient 1 also had an early age at onset, as dictated by the inclusion criteria for the
discovery sample. Case patient 5 was diagnosed with schizophrenia at age 21 years, while
case patient 3 was first admitted to the hospital for psychiatric illness at age 41 years. We
observed a tendency for intellectual disability and developmental delay among the case
carriers, since three have mild intellectual disability and five have developmental delay
(Table 1). Neuropsychiatric evaluation of the five comparison carriers has not been
performed, and therefore we do not know whether they share some features with the case
patients. All of the case patients have a family history of psychiatric illness. Unfortunately,
we do not have access to DNA samples for most of the affected relatives, and we only know
the duplication status for three of these relatives as follows: the mother of case patient 5 has
bipolar disorder and carries the 15q11-q13 duplication; the brother of case patient 6 has
bipolar disorder but does not carry the duplication; and the sister of case patient 7 had
idiopathic seizures in early childhood and has ADHD but does not carry the duplication.
This suggests that in these families, the 15q11-q13 duplications are not the sole mechanisms
underpinning disease, a phenomenon that has been noted previously (18). We found no
additional large (>500 Kb) copy number variants among the 12 15q11-q13 duplication
carriers, and therefore we cannot pinpoint a “two-hit” copy number variant model mediating
the developmental phenotype, as was suggested for microdeletions at chromosome 16p12.1
in a recent study (24).
Origin of Duplications in Carriers
Both parents of case patient 7 have been genotyped on single nucleotide polymorphism
microarrays, and therefore we could determine that the duplication is de novo in this patient.
Through analysis of the genotypes in case 7 and in the parents of this patient, we could
determine that the duplicated alleles were derived from both chromosomes of the patient’s
mother, suggesting interchromosomal nonallelic homologous recombination (25) as the
mutational mechanism. Furthermore, for comparison subject 1, analysis of microsatellite
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genotypes from other family members revealed that the duplication is present de novo in the
subject’s father, most likely through an interchromosomal nonallelic homologous
recombination in the father’s germline (see section 4 in the data supplement). This evidence
is consistent with the notion that most deletions and duplications in the 15q11-q13 region
are mediated through nonallelic homologous recombination between the low copy repeat
regions associated with BP1–BP5 (reviewed in 19) (Figure 1) and that large duplications
derived through this mechanism most often occur via interchromosomal crossover (26).
Medical records for case patient 5 show that the duplication was transmitted to the patient
from the mother (established through a clinical genetics analysis of the patient and the
patient’s mother performed prior to the present study). DNA samples were not available for
parents of other carriers, and therefore we could not assess whether the duplications in these
individuals are de novo or inherited.
Discussion
Duplications of the Prader-Willi/Angelman critical region are a recognized genomic
syndrome (OMIM number: 608636), wherein the most commonly observed features include
autism, developmental delay, intellectual disability, seizures, and hypotonia. In most cases
where the parental origin of the duplications has been assessed, the syndrome-associated
features were present only when duplications were maternally derived (14–16), although a
developmental phenotype has been observed in single carriers of paternally derived
duplications (reviewed in 19).
In the present study, we report that maternally derived 15q11-q13 duplications may also act
as risk factors for schizophrenia and related psychoses. The carriers with psychosis also
show known features of 15q11-q13 duplication syndrome and other genomic syndromes
(e.g., developmental delay and intellectual disability) (Table 1). However, other features,
including seizures and hypotonia, were not observed in the medical records available to us
for the carriers. Only one of the carriers with psychotic illness has a previous diagnosis of
autism (case 2). The other carriers have no known history of autistic features, and therefore
we judge it unlikely that they represent autism patients misdiagnosed as schizophrenia
patients.
Although the occurrence of 15q11-q13 duplications in schizophrenia and psychotic illness is
rare, and the significance level of association is nominal (p=0.01), the hypothesis for
association is supported by two independent lines of evidence. The first comes from
observed differences in the clinical manifestation of the various genotypes causing Prader-
Willi and Angelman syndromes (27, 28). Angelman syndrome arises from disruptions that
lead to a lack of maternally expressed gene product(s), maternally derived deletions of the
critical interval, paternal uniparental disomy, and mutations of the key maternally expressed
imprinted gene UBE3A. Patients with Angelman syndrome have severe to profound mental
retardation, microcephaly, seizures, and ataxia and almost always lack speech (29, 30).
Prader-Willi syndrome is caused in approximately 70% of cases by deletion of the paternal
chromosome for the critical region (27). Most other cases have maternal uniparental disomy,
having received two maternal copies of the region, with the paternal chromosome being
absent. Rare cases are caused by mutations in the imprinting center, leading to methylation
defects. Despite diverse mechanisms, all individuals with Prader-Willi syndrome have in
common a lack of paternally expressed gene product(s). Prader-Willi syndrome is
characterized by a failure to thrive in infancy, mild learning disabilities, and, on emerging
from infancy, an abnormal satiety response to food intake and obsession with food, sexual
immaturity, short stature, and a characteristic physical phenotype (31). In addition to these
core deficits, individuals with Prader-Willi syndrome are prone to affective disorders,
including mood instability, nonpsychotic depression, and psychosis, features not observed in
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Angelman syndrome (29, 30). Moreover, and of particular relevance to our finding, Prader-
Willi syndrome resulting from maternal uniparental disomy is several-fold more frequently
associated with psychotic episodes than the paternal deletion subtype (Table 2). This has
been reported in three independent studies from different countries. One study on Prader-
Willi syndrome conducted in the United Kingdom identified psychotic illness at a
significantly higher rate in 33 patients with maternal uniparental disomy compared with 82
patients with paternal deletions (61.8% versus 16.5%, respectively, p<0.001, odds ratio=8.2)
(27). Two other studies also reported that the maternal uniparental disomy subtype is
associated with mixed symptoms of bipolar mood disorder and psychosis at high frequencies
(32, 33). Together, these studies suggest that having two maternal copies of the chromosome
(leading to overexpression of maternally derived genes) is the important factor for risk of
psychosis in Prader-Willi syndrome, rather than the loss of expression of genes from the
paternal chromosome. This is consistent with our observation of overrepresentation of
maternally derived duplication of the 15q11-q13 region in schizophrenia and schizoaffective
disorder. Interestingly, among the carriers identified in our study, case patient 3 has a
schizoaffective disorder, case patient 5 (schizophrenia) has prominent affective symptoms,
and case patient 6 (bipolar disorder) also has prominent psychotic features (see section 3 in
the data supplement), similar to the common presentations reported by both Vogels et al.
(33) and Verhoeven et al. (34).
The second line of evidence comes from the confirmed role of 15q11-q13 duplications in the
etiology of autism (17–19). As discussed in the introduction, there is now a strong and
growing body of evidence that autism and psychotic illness partially share genetic etiology,
with copy number variants that associate with schizophrenia and related psychoses also
being observed at elevated rates in autism. Our current finding adds another locus to the list
of copy number variants that increase susceptibility to both disorders.
The 15q11-q13 region contains a cluster of imprinted genes (genes that are expressed only
when transmitted from either mother or father but not both). Several of these are only
expressed from the paternal chromosome, while at least one gene, UBE3A, is only
expressed from the maternal chromosome and is robustly imprinted in the brain (35). The
product of this gene, E6-AP ubiquitin ligase, regulates the degradation of certain proteins in
neurons such as the synaptic protein Arc, which promotes the internalization of AMPA
receptors at excitatory synapses, thus linking UBE3A to regulation of glutamatergic
signaling and synaptic development (35). A mouse model lacking UBE3A shows impaired
long-term potentiation in the hippocampus and, consequently, a learning and memory deficit
(36). Another gene in the region, ATP10A, encoding an amino-phospholipid-transporting
ATPase involved in transporting phosphatidylserine and phosphatidylethanolamine from
one side of a lipid bilayer to another, is of unknown imprinting status but is probably
maternally expressed in the brain in at least some individuals (possibly depending on
gender) (37), while the mouse ATP10A is not imprinted in the brain (38).
Chromosome 15 harbors several loci implicated in schizophrenia and other
neurodevelopmental disorders. There is a series of low copy repeat regions near the
centromere. Such regions are liable to create nonallelic homologous recombination between
the parental chromosomes because of the high homology between these repeats, resulting in
deletions or duplications of the regions in between (25). There are five well-recognized low
copy repeat regions in the 15q11-q13 region (commonly termed BP1–BP5, reviewed in
Hogart et al. [19]). Our finding differs from previous findings concerning the 15q proximal
region, which have implicated deletions at 15q11.2 between BP1 and BP2 (chromosome 15:
20,306,549–20,777,695) and at 15q13.3 between BP4 and BP5 (chromosome 15:
28,723,577–30,302,218) in schizophrenia (2–4) as well as duplications in general occurring
within the BP1–BP5 region in autism, intellectual disability, and schizophrenia (39). The
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study by Itsara et al. (39) combined data from different genome-wide copy number variant
studies, and in fact the only schizophrenia case reported by these authors is that of case
patient 4 in the present study (first reported by the International Schizophrenia Consortium
[3]). Our data, together with previous findings of high occurrence of psychosis in the
maternal uniparental disomy subtype of Prader-Willi syndrome (40), suggest that maternally
expressed gene products in the region between BP2 and BP3 (Figure 1) might be involved in
mediating risk of psychosis. Also, our study provides new suggestive evidence of psychotic
illness belonging to the phenotypic spectrum of the 15q11-q13 microduplication syndrome
(OMIM number: 608636).
A limitation to our study, however, is the rarity of 15q11-q13 duplications in schizophrenia
and related psychoses in general, and therefore a follow-up study of individuals with 15q11-
q13 microduplication syndrome is needed to estimate the prevalence of psychotic features in
adult-hood in the syndrome. Another limitation is the lack of DNA samples from close
family members of most of the identified carriers to determine transmission status of the
duplications and cosegregation with illness. Also, we have no neuropsychiatric assessment
of the carriers identified among comparison subjects. These are individuals who have
participated in various genetic studies at deCODE Genetics (diagnosis is provided in Table 1
for the two who participated as patients in a specific disease study). All five subjects were
adults at the time of their recruitment, and therefore it is unlikely that they have a severe
form of the duplication syndrome. Our study, together with that of Glessner et al. (18),
provides a good estimate of the prevalence of maternally derived 15q11-q13 duplications in
autism and schizophrenia spectrum disorders as well as in the control population, with a
prevalence of 0.5–1 out of 100, 1,000, and 10,000 individuals, respectively.
In conclusion, our findings of schizophrenia and psychotic illness in carriers of maternally
derived 15q11-q13 duplications suggest that an excess of maternally expressed gene
products in this region may be involved in the etiology of psychosis. Although rare in
psychotic illness compared with autism spectrum disorders (0.05% versus 0.6%,
respectively), exploration of the effects of this duplication in model systems has the
potential to provide insight into the biological processes underlying psychosis.
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FIGURE 1. The Chromosome 15q11.2-q13.3 regiona
a
 The data depict chromosomal coordinates according to the National Center for
Biotechnology Information Build 36 (top), followed by chromosome bands, annotated genes
from the National Center for Biotechnology Information Reference Sequence database,
tracks indicating the Southern hybridization probe, microsatellites used to determine
duplication origin, tracks indicating the duplications identified in the present study, and
segmental duplications in the region, with common breakpoints (BPs) of Prader-Willi and
Angelman syndromes (BP1–BP5). All duplications were maternally derived except two of
the comparison duplications, which were paternally derived (gray bars). (Figure adapted
with permission from the Human [Homo Sapiens] Genome Browser Gateway [http://
genome.ucsc.edu/]. Kent WJ, Sugnet CW, Furey TS, Roskin KM, Pringle TH, Zahler AM,
Haussler D: The Human Genome Browser at UCSC. Genome Res 2002; 12:996-1006).
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